Dr Christos Kyriakopoulos speaks to ecancer at ASCO 2024 about results from the CHAARTED2 trial which evaluated cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel.
223 patients with metastatic CRPC previously treated with ADT + docetaxel for HSPC were randomized (1:1) to abiraterone/prednisone plus cabazitaxel or abiraterone/prednisone alone.
Dr Kyriakopoulos reports that a PFS benefit of 5 months was seen with patients who received the added cabazitaxel.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php